Literature DB >> 15963094

Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

Mari Thörn1, Niklas Finnström, Stefan Lundgren, Anders Rane, Lars Lööf.   

Abstract

AIM: The aim of this study was to quantify the mRNA expression of three cytochromes P450 (CYP) and P-glycoprotein (P-gp) in the human gastrointestinal (GI) tract.
METHOD: Biopsies were obtained from gastric, duodenal, colonic and rectal mucosa during routine gastro-colonoscopy in 27 patients. The biopsies were snap-frozen in liquid nitrogen. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was used for the quantitative analyses of mRNA expressed by the CYP2E1, CYP3A4 and CYP3A5 genes, and the MDR1 gene coding for P-gp protein. The mRNA expression of b-actin was used as an internal standard for comparisons between samples.
RESULTS: All CYP genes were expressed at all locations throughout the GI tract, although all showed substantial interindividual variation. CYP2E1 had the highest expression at all locations (P < 0.05 to P < 0.0001), except in the right colon. CYP3A4 and CYP3A5 had their highest mRNA expression in the duodenum (P < 0.001 and P < 0.000 001, respectively) and CYP2E1 in the stomach (P < 0.01). MDR1 mRNA concentrations increased along the GI tract with the highest expression being in the left colon (P < 0.000001).
CONCLUSION: Multiple sampling within the same individual enabled us to study the intraindividual variation in expression of CYP and MDR1 genes along the GI tract. We find that CYP2E1 mRNA expression is higher than that of the other CYPs. CYP3A expression is highest in the duodenum and that of MDR1 increases from stomach and duodenum to colon.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963094      PMCID: PMC1884914          DOI: 10.1111/j.1365-2125.2005.02389.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  37 in total

1.  Does the CYP3A5*3 polymorphism affect in vivo drug elimination?

Authors:  Kenneth E Thummel
Journal:  Pharmacogenetics       Date:  2003-10

Review 2.  Molecular genetics of the P-450 superfamily.

Authors:  F J Gonzalez
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease.

Authors:  N Finnström; M Thörn; L Lööf; A Rane
Journal:  Eur J Clin Pharmacol       Date:  2001-08       Impact factor: 2.953

4.  Characterization of human small intestinal cytochromes P-450.

Authors:  Q Y Zhang; D Dunbar; A Ostrowska; S Zeisloft; J Yang; L S Kaminsky
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

5.  Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine.

Authors:  R H Stephens; J Tanianis-Hughes; N B Higgs; M Humphrey; G Warhurst
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

6.  Gene expression of cytochromes P450 in liver transplants over time.

Authors:  Mari Thörn; Stefan Lundgren; Gustaf Herlenius; Bo-Göran Ericzon; Lars Lööf; Anders Rane
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

7.  CYP3A gene expression in human gut epithelium.

Authors:  J C Kolars; K S Lown; P Schmiedlin-Ren; M Ghosh; C Fang; S A Wrighton; R M Merion; P B Watkins
Journal:  Pharmacogenetics       Date:  1994-10

8.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

Authors:  K S Lown; J C Kolars; K E Thummel; J L Barnett; K L Kunze; S A Wrighton; P B Watkins
Journal:  Drug Metab Dispos       Date:  1994 Nov-Dec       Impact factor: 3.922

9.  Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues.

Authors:  R A McKinnon; W M Burgess; P M Hall; S J Roberts-Thomson; F J Gonzalez; M E McManus
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

10.  P-glycoprotein increases from proximal to distal regions of human small intestine.

Authors:  Stéphane Mouly; Mary F Paine
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

View more
  38 in total

Review 1.  Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations.

Authors:  Simon Tremblay; Rita R Alloway
Journal:  AAPS J       Date:  2017-07-17       Impact factor: 4.009

Review 2.  The pharmacology of novel oral anticoagulants.

Authors:  Tracy A DeWald; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 3.  Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.

Authors:  Stefan Oswald; Christian Gröer; Marek Drozdzik; Werner Siegmund
Journal:  AAPS J       Date:  2013-08-28       Impact factor: 4.009

4.  Role of xenobiotic-metabolizing enzyme gene polymorphisms and interactions with environmental factors in susceptibility to gastric cancer in Kashmir Valley.

Authors:  Manzoor A Malik; Rohit Upadhyay; Rama D Mittal; Showket A Zargar; Dinesh R Modi; Balraj Mittal
Journal:  J Gastrointest Cancer       Date:  2009-06-12

Review 5.  HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities.

Authors:  Corbin G Thompson; Cynthia L Gay; Angela D M Kashuba
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-16       Impact factor: 2.205

Review 6.  Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

Review 7.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

8.  High-fat diet alters gene expression in the liver and colon: links to increased development of aberrant crypt foci.

Authors:  Sara Padidar; Andrew J Farquharson; Lynda M Williams; Rebecca Kearney; John R Arthur; Janice E Drew
Journal:  Dig Dis Sci       Date:  2012-02-29       Impact factor: 3.199

9.  Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers.

Authors:  Frank Stifft; Floris Vanmolkot; Ingrid Scheffers; Luc van Bortel; Cees Neef; Maarten Christiaans
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

10.  Polymorphisms of xenobiotic-metabolizing and transporter genes, and the risk of gastric and colorectal cancer in an admixed population from the Brazilian Amazon.

Authors:  Amanda Nazaré Cohen Lima de Castro; Marianne Rodrigues Fernandes; Darlen Cardoso de Carvalho; Tatiane Piedade de Souza; Juliana Carla Gomes Rodrigues; Roberta Borges Andrade; Antonio Andre Conde Modesto; Sidney Santos; Paulo Pimentel Assumpção; Ney Pereira Carneiro Dos Santos
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.